Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
J Otolaryngol Head Neck Surg
2021 Mar 09;501:15. doi: 10.1186/s40463-021-00493-2.
Show Gene links
Show Anatomy links
Canadian Rhinology Working Group consensus statement: biologic therapies for chronic rhinosinusitis.
Thamboo A
,
Kilty S
,
Witterick I
,
Chan Y
,
Chin CJ
,
Janjua A
,
Javer A
,
Lee J
,
Monterio E
,
Rotenberg B
,
Scott J
,
Smith K
,
Sommer DD
,
Sowerby L
,
Tewfik M
,
Wright E
,
Desrosiers M
.
???displayArticle.abstract???
BACKGROUND: Recent evidence suggests that biologic therapy with targeted activity within the Type 2 inflammatory pathway can improve the clinical signs and symptoms of chronic rhinosinusitis with nasal polyposis (CRSwNP). There remains a population in CRSwNP that despite medical therapy and endoscopic sinus surgery have persistent signs and symptoms of disease. Therefore, biologics, monoclonal antibody agents, could be beneficial therapeutic treatments for these patients. There have been eight randomized, double-blind, placebo-controlled trails performed for CRSwNP targeted components of the Type 2 inflammatory pathway, notably interleukin (IL)-4, IL-5 and IL-13, IL-5R, IL-33, and immunoglobulin (Ig)E. However, there are no formal recommendations for the optimal use of biologics in managing Chronic Rhinosinusitis (CRS) within the Canadian health care environment.
METHODS: A Delphi Method process was utilized involving three rounds of questionnaires in which the first two were completed individually online and the third was discussed on a virtual platform with all the panelists. 17 fellowship trained rhinologists across Canada evaluated the 28 original statements on a scale of 1-10 and provided comments. A rating within 1-3 indicated disagreement, 8-10 demonstrated agreement and 4-7 represented being neutral towards a statement. All ratings were quantitively reviewed by mean, median, mode, range and standard deviation. Consensus was defined by removing the highest and lowest of the scores and using the "3 point relaxed system".
RESULTS: After three rounds, a total of 11 statements achieved consensus. This white paper only contains the final agreed upon statements and clear rationale and support for the statements regarding the use of biologics in patients with CRS.
CONCLUSION: This white paper provides guidance to Canadian physicians on the use of biologic therapy for the management of patients with CRS, but the medical and surgical regimen should ultimately be individualized to the patient. As more biologics become available and additional trials are published we will provide updated versions of this white paper every few years.
Au,
Cost of outpatient endoscopic sinus surgery from the perspective of the Canadian government: a time-driven activity-based costing approach.
2013, Pubmed
Au,
Cost of outpatient endoscopic sinus surgery from the perspective of the Canadian government: a time-driven activity-based costing approach.
2013,
Pubmed
Bachert,
Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial.
2016,
Pubmed
Bachert,
Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial.
2017,
Pubmed
Bachert,
Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP.
2020,
Pubmed
Deleuran,
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.
2020,
Pubmed
Desrosiers,
Canadian clinical practice guidelines for acute and chronic rhinosinusitis.
2011,
Pubmed
Di Bona,
Long-term "real-life" safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study.
2017,
Pubmed
Fokkens,
European Position Paper on Rhinosinusitis and Nasal Polyps 2020.
2020,
Pubmed
Gevaert,
Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps.
2006,
Pubmed
Gevaert,
Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis.
2011,
Pubmed
Gevaert,
Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma.
2013,
Pubmed
Hopkins,
Long-term outcomes from the English national comparative audit of surgery for nasal polyposis and chronic rhinosinusitis.
2009,
Pubmed
Hox,
Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper.
2020,
Pubmed
Iqbal,
The role of biologics in chronic rhinosinusitis: a systematic review.
2020,
Pubmed
Jones,
Consensus methods for medical and health services research.
1995,
Pubmed
Palmer,
EXHANCE-12: 1-year study of the exhalation delivery system with fluticasone (EDS-FLU) in chronic rhinosinusitis.
2018,
Pubmed
Pinto,
A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis.
2010,
Pubmed
Quintanilla-Dieck,
Comparison of disease-specific quality-of-life instruments in the assessment of chronic rhinosinusitis.
2012,
Pubmed
Rosati,
Relationships among allergic rhinitis, asthma, and chronic rhinosinusitis.
2016,
Pubmed
Scangas,
Cost Utility Analysis of Dupilumab Versus Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps.
2021,
Pubmed
Smith,
Long-term revision rates for endoscopic sinus surgery.
2019,
Pubmed
Smith,
Biologics in Chronic Rhinosinusitis: An Update and Thoughts for Future Directions.
2018,
Pubmed
Stein,
Revision rates and time to revision following endoscopic sinus surgery: A large database analysis.
2018,
Pubmed
Tait,
Effect of Budesonide Added to Large-Volume, Low-pressure Saline Sinus Irrigation for Chronic Rhinosinusitis: A Randomized Clinical Trial.
2018,
Pubmed